Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer

NAARDEN, Netherlands & WALTHAM, Mass.–(BUSINESS WIRE)–Prilenia Therapeutics B.V., a scientific stage biotechnology firm targeted on the pressing mission to develop novel therapeutics to gradual the development of neurodegenerative and neurodevelopmental problems, right this moment introduced the appointment of Anne Sullivan as Chief Enterprise Officer. On this function, Ms. Sullivan will lead all strategic collaboration actions.

“As Prilenia prepares for key milestones in its pipeline over the approaching months, we imagine Anne brings large expertise and perspective to our management workforce,” mentioned Dr. Michael R. Hayden, CEO and Founding father of Prilenia. “We’re delighted to welcome Anne to the workforce and are assured that her robust background in neurology and experience in company and enterprise growth shall be invaluable as Prilenia takes essential steps towards its future.”

“Prilenia represents a company really dedicated to scientific rigor in addition to to folks residing with severe neurological illnesses, like Huntington’s illness and ALS, and I couldn’t be extra happy to affix the workforce and advance its mission,” mentioned Anne Sullivan, Chief Enterprise Officer at Prilenia. “Prilenia is poised to make vital progress over the subsequent few quarters, with the Firm anticipating key knowledge from its ongoing research of pridopidine in ALS and Huntington’s illness. Figuring out that many individuals are ready for potential new therapeutic choices, we’re actively evaluating alternatives to speed up and increase the potential impression of pridopidine.”

Anne brings greater than 25 years of expertise within the biopharmaceutical trade. Previous to becoming a member of Prilenia, Anne served as Chief Enterprise Officer at Rodin Therapeutics, a privately held scientific stage biopharmaceutical firm discovering and creating first-in-class therapeutics for severe neurological illnesses. Anne performed an instrumental function within the acquisition of Rodin by Alkermes plc in November 2019 and has since then served as consulting CBO for a number of personal and public biopharma corporations. Earlier than becoming a member of Rodin, Anne served as Senior Vice President, Company Improvement & Operations at Sea Prescribed drugs, LLC, and Vice President, Company Improvement and Licensing with Sunovion Prescribed drugs Inc. (previously Sepracor Inc.). She started her profession as an authorized public accountant working in audit and worldwide finance with KPMG and Wang Laboratories. Anne obtained an A.B. in economics/accounting from the School of the Holy Cross and an MBA from the Tuck Faculty of Enterprise at Dartmouth School.

About Prilenia

Prilenia is a scientific stage biotech startup based in 2018 targeted on the pressing mission to develop novel therapeutics to gradual the development of neurodegenerative illnesses and neurodevelopmental problems.

The Firm’s lead asset, pridopidine, is an oral, extremely selective Sigma-1 Receptor agonist that’s presently being assessed in scientific research as a possible therapy choice for folks residing with Huntington’s illness (HD) in addition to ALS.

Prilenia is backed by a bunch of well-respected buyers together with: Forbion, Morningside, Sands Capital, SV Well being Traders, Sectoral Asset Administration, Talisman, Amplitude Ventures and the ALS Funding Fund. The Firm is predicated in Naarden, the Netherlands, Herzliya, Israel and Waltham, Mass. within the U.S.

For extra data go to www.prilenia.com and comply with us on LinkedIn and Twitter.

^©2022 Prilenia Therapeutics B.V.

For a replica of this launch, go to Prilenia’s web site at www.prilenia.com